Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.4K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.4K
RNA Splicing01:32

RNA Splicing

61.0K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
61.0K
Alternative RNA Splicing02:18

Alternative RNA Splicing

25.4K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
25.4K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

8.1K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
8.1K
Pre-mRNA Processing: RNA Splicing01:36

Pre-mRNA Processing: RNA Splicing

7.2K
7.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The mechanism of intestinal IgA class switching regulated by TRIM21 through down-regulation of AID in IgA nephropathy.

International immunopharmacology·2026
Same author

<i>Ex vivo</i> bradykinin as a functional biomarker for angioedema with normal C1-inhibitor.

The journal of allergy and clinical immunology. Global·2026
Same author

Association of endothelial activation and stress index with all-cause and cardiovascular mortality in patients with diabetic kidney disease: a population-based prospective study.

Diabetology & metabolic syndrome·2026
Same author

RETRACTED ARTICLE: AI-Empowered assistive technology for optimizing specimen submission in obstetrics and gynecology: integrating DeepSeek with the ADDIE model.

Disability and rehabilitation. Assistive technology·2025
Same author

Bradykinin measurement by liquid chromatography tandem mass spectrometry in subjects with hereditary angioedema enhanced by cold activation.

The journal of allergy and clinical immunology. Global·2025
Same author

Vamp3/syntaxin 4 mediates the basolateral membrane fusion of TfR transcytosis across the BBB and is exploited by pathogenic <i>E. coli</i>.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same journal

A viral ORFeome library for systems-level genetic dissection of host-pathogen interactions.

Cell·2026
Same journal

Co-option of lysosomal machinery shapes the evolution of the intracellular photosymbiosis supporting coral reefs.

Cell·2026
Same journal

LEF1 and niche factors determine T cell stemness across chronic diseases.

Cell·2026
Same journal

Recurrent patterns of TOP1-mediated neuronal genomic damage shared by major neurodegenerative disorders.

Cell·2026
Same journal

Four-dimensional molecular mapping from a spatial snapshot reveals the dynamics of hair follicle organogenesis.

Cell·2026
Same journal

Whole-cell particle-based digital twin simulations from 4D lattice light-sheet microscopy data.

Cell·2026
See all related articles

Related Experiment Video

Updated: Feb 27, 2026

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

14.5K

Splicing-Correcting Therapy for SMA.

Lili Wan1, Gideon Dreyfuss1

  • 1Howard Hughes Medical Institute, Department of Biochemistry and Biophysics, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA.

Cell
|July 1, 2017
PubMed
Summary
This summary is machine-generated.

Spinal muscular atrophy (SMA) is a genetic disease caused by low SMN protein. Antisense treatment targeting SMN2 intron 7 splicing silencer can improve SMN expression and motor function in SMA patients.

More Related Videos

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
05:55

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice

Published on: October 3, 2011

63.5K
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

7.2K

Related Experiment Videos

Last Updated: Feb 27, 2026

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

14.5K
Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
05:55

Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice

Published on: October 3, 2011

63.5K
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

7.2K

Area of Science:

  • Genetics
  • Molecular Biology
  • Neuroscience

Background:

  • Spinal muscular atrophy (SMA) results from a deficiency in the survival motor neuron (SMN) protein, essential for spliceosome biogenesis.
  • Most SMA patients possess SMN1 deletions, relying on SMN2 as their primary SMN protein source.
  • A specific C-to-T substitution in SMN2 alters splicing by converting an exonic splicing enhancer (ESE) to an exonic splicing silencer (ESS), leading to exon 7 skipping.

Purpose of the Study:

  • To investigate the therapeutic potential of targeting the SMN2 gene for treating spinal muscular atrophy.
  • To evaluate the efficacy of antisense treatment directed at the SMN2 intron 7 splicing silencer (ISS) in improving SMN expression and motor function.

Main Methods:

  • Analysis of SMN protein deficiency in spinal muscular atrophy (SMA).
  • Investigation of the molecular mechanism of exon 7 skipping in SMN2 pre-mRNA due to a C-to-T substitution.
  • Application of antisense treatment targeting the SMN2 intron 7 splicing silencer (ISS).

Main Results:

  • Antisense treatment targeting the SMN2 intron 7 splicing silencer (ISS) was shown to improve SMN expression.
  • The treatment also led to improvements in motor function in SMA patients.

Conclusions:

  • Targeting the SMN2 intron 7 splicing silencer (ISS) with antisense technology represents a promising therapeutic strategy for spinal muscular atrophy (SMA).
  • This approach can effectively enhance SMN protein levels and ameliorate motor deficits, offering a potential treatment pathway for SMA patients.